Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

KRN 8602 9-ethyl-4,6,9,10,11- pentahydroxy-7-(5...

Synonyms: LS-94099, AC1L55Y3, 131722-57-1, MX2 hydrochloride

This record was replaced with 107869.

Clarke, K. et al., Morgan, D.J. et al., Clarke, K. et al.

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Morpholinyl oxaunomycin

KRN8602 (MX2-hydrochloride): an active new agent for the treatment of recurrent high-grade glioma [1].
PURPOSE: To determine the recommended dose, toxicity profile, and pharmacokinetics of KRN8602 (MX2-hydrochloride), a novel morpholino anthracycline with potent cytotoxicity against anthracycline-sensitive and resistant experimental tumors in vitro and in vivo [2].

High impact information on Morpholinyl oxaunomycin

Effect of filgrastim on the pharmacokinetics of MX2 hydrochloride in patients with advanced malignant disease [3].

References

KRN8602 (MX2-hydrochloride): an active new agent for the treatment of recurrent high-grade glioma. Clarke, K., Basser, R.L., Underhill, C., Mitchell, P., Bartlett, J., Cher, L., Findlay, M., Dalley, D., Pell, M., Byrne, M., Geldard, H., Hill, J.S., Maher, D., Fox, R.M., Green, M.D., Kaye, A.H. J. Clin. Oncol. (1999) [Pubmed]
Phase I and pharmacokinetic study of KRN8602 alone and with filgrastim in patients with advanced cancer. Clarke, K., Basser, R.L., Maher, D., Morgan, D.J., Cebon, J., Fox, R.M., Hill, J.S., Alt, C., Bartlett, J., Geldard, H., Kaye, A.H., Green, M.D. J. Clin. Oncol. (1998) [Pubmed]
Effect of filgrastim on the pharmacokinetics of MX2 hydrochloride in patients with advanced malignant disease. Morgan, D.J., Hill, J.S., Clarke, K., Stylli, S.S., Park, S.J., Cebon, J., Basser, R.L., Kaye, A.H., Geldard, H., Maher, D.W., Green, M.D. Cancer Chemother. Pharmacol. (1998) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

Editor

Share